Oral Probiotic Microcapsule Formulation Ameliorates Non-Alcoholic Fatty Liver Disease in Bio F1B Golden Syrian Hamsters

Abstract

The beneficial effect of a microencapsulated feruloyl esterase producing Lactobacillus fermentum ATCC 11976 formulation for use in non-alcoholic fatty liver disease (NAFLD) was investigated. For which Bio F1B Golden Syrian hamsters were fed a methionine deficient/choline devoid diet to induce non-alcoholic fatty liver disease. Results, for the first time, show significant clinical benefits in experimental animals. Examination of lipids show that concentrations of hepatic free cholesterol, esterified cholesterol, triglycerides and phospholipids were significantly lowered in treated animals. In addition, serum total cholesterol, triglycerides, uric acid and insulin resistance were found to decrease in treated animals. Liver histology evaluations showed reduced fat deposits. Western blot analysis shows significant differences in expression levels of key liver enzymes in treated animals. In conclusion, these findings suggest the excellent potential of using an oral probiotic formulation to ameliorate NAFLD.

Oral administration of Lactobacillus fermentum CRL1446 improves biomarkers of metabolic syndrome in mice fed a high-fat diet supplemented with wheat bran

“…The MS+Lf group showed a 39% decrease in the adiposity index compared to MS group (Table 1). These results are in accordance with those of Bhathena et al 8 , who observed a reduction in the adiposity index when L. fermentum ATCC11976, strain with FE activity, was administered to hamsters with MS.…”

“…Regarding to LDL-cholesterol, in MS group a 26% increase in the levels of this lipoprotein was observed compared to control group, while the administration of L. fermentum CRL1446 (MS+Lf) reduced LDL-cholesterol levels to values similar to those detected in the control group. These results were similar to those observed by Bhathena et al8 in hamsters with MS treated with L. fermentun ATCC11976, strain with FE activity.MS group showed a 56% increase in triglyceride levels compared to control group. In MS+Lf group, hypertriglyceridemia was reduced to values similar to the control group.…”

Oral administration of Lactobacillus fermentum CRL1446 improves biomarkers of metabolic syndrome in mice fed a high-fat diet supplemented with wheat bran

“…The MS+Lf group showed a 39% decrease in the adiposity index compared to MS group (Table 1). These results are in accordance with those of Bhathena et al 8 , who observed a reduction in the adiposity index when L. fermentum ATCC11976, strain with FE activity, was administered to hamsters with MS.…”

“…Regarding to LDL-cholesterol, in MS group a 26% increase in the levels of this lipoprotein was observed compared to control group, while the administration of L. fermentum CRL1446 (MS+Lf) reduced LDL-cholesterol levels to values similar to those detected in the control group. These results were similar to those observed by Bhathena et al8 in hamsters with MS treated with L. fermentun ATCC11976, strain with FE activity.MS group showed a 56% increase in triglyceride levels compared to control group. In MS+Lf group, hypertriglyceridemia was reduced to values similar to the control group.…”

Efficacy of probiotics in non‐alcoholic fatty liver disease in adult and children: A meta‐analysis of randomized controlled trials

“…5 Accumulation of cholesterol, especially derived from biosynthetic routes, alters the intracellular cholesterol transportation and homeostasis, thus leading to liver injury and steatosis, inflammation, and fibrosis. 21,22 The results of the current and previous studies 18,23 consistently support the notion that probiotics have an effect on reducing T-chol levels in NAFLD patients. The disturbance of lipid metabolism was present in NAFLD 24,25 and probiotics may effectively regulate the blood lipids to a beneficial direction in NAFLD patients.…”

Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease

“…Similar to our results, Aller et al (2011), in a pilot study on individuals with NAFLD, did not find significant changes in blood glucose after a 3-mo intervention using Lactobacillus bulgaricus and Streptococcus thermophilus. In the study of Bhathena et al (2013), treatment with Lactobacillus fermentum for 12 wk had no significant effect on glucose levels in hamsters. On the other hand, in some animal and human studies, probiotics improved serum elevated glucose (Paik et al, 2005;Yadav et al, 2008;Ejtahed et al, 2011).…”

Oral administration of Lactobacillus fermentum CRL1446 improves biomarkers of metabolic syndrome in mice fed a high-fat diet supplemented with wheat bran

“…The MS+Lf group showed a 39% decrease in the adiposity index compared to MS group (Table 1). These results are in accordance with those of Bhathena et al 8 , who observed a reduction in the adiposity index when L. fermentum ATCC11976, strain with FE activity, was administered to hamsters with MS.…”

“…Regarding to LDL-cholesterol, in MS group a 26% increase in the levels of this lipoprotein was observed compared to control group, while the administration of L. fermentum CRL1446 (MS+Lf) reduced LDL-cholesterol levels to values similar to those detected in the control group. These results were similar to those observed by Bhathena et al8 in hamsters with MS treated with L. fermentun ATCC11976, strain with FE activity.MS group showed a 56% increase in triglyceride levels compared to control group. In MS+Lf group, hypertriglyceridemia was reduced to values similar to the control group.…”

Efficacy of probiotics in non‐alcoholic fatty liver disease in adult and children: A meta‐analysis of randomized controlled trials

“…5 Accumulation of cholesterol, especially derived from biosynthetic routes, alters the intracellular cholesterol transportation and homeostasis, thus leading to liver injury and steatosis, inflammation, and fibrosis. 21,22 The results of the current and previous studies 18,23 consistently support the notion that probiotics have an effect on reducing T-chol levels in NAFLD patients. The disturbance of lipid metabolism was present in NAFLD 24,25 and probiotics may effectively regulate the blood lipids to a beneficial direction in NAFLD patients.…”

Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease

“…Similar to our results, Aller et al (2011), in a pilot study on individuals with NAFLD, did not find significant changes in blood glucose after a 3-mo intervention using Lactobacillus bulgaricus and Streptococcus thermophilus. In the study of Bhathena et al (2013), treatment with Lactobacillus fermentum for 12 wk had no significant effect on glucose levels in hamsters. On the other hand, in some animal and human studies, probiotics improved serum elevated glucose (Paik et al, 2005;Yadav et al, 2008;Ejtahed et al, 2011).…”

Oral administration of Lactobacillus fermentum CRL1446 improves biomarkers of metabolic syndrome in mice fed a high-fat diet supplemented with wheat bran

“…The MS+Lf group showed a 39% decrease in the adiposity index compared to MS group (Table 1). These results are in accordance with those of Bhathena et al 8 , who observed a reduction in the adiposity index when L. fermentum ATCC11976, strain with FE activity, was administered to hamsters with MS.…”

“…Regarding to LDL-cholesterol, in MS group a 26% increase in the levels of this lipoprotein was observed compared to control group, while the administration of L. fermentum CRL1446 (MS+Lf) reduced LDL-cholesterol levels to values similar to those detected in the control group. These results were similar to those observed by Bhathena et al8 in hamsters with MS treated with L. fermentun ATCC11976, strain with FE activity.MS group showed a 56% increase in triglyceride levels compared to control group. In MS+Lf group, hypertriglyceridemia was reduced to values similar to the control group.…”

Efficacy of probiotics in non‐alcoholic fatty liver disease in adult and children: A meta‐analysis of randomized controlled trials

“…5 Accumulation of cholesterol, especially derived from biosynthetic routes, alters the intracellular cholesterol transportation and homeostasis, thus leading to liver injury and steatosis, inflammation, and fibrosis. 21,22 The results of the current and previous studies 18,23 consistently support the notion that probiotics have an effect on reducing T-chol levels in NAFLD patients. The disturbance of lipid metabolism was present in NAFLD 24,25 and probiotics may effectively regulate the blood lipids to a beneficial direction in NAFLD patients.…”

Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease

“…Similar to our results, Aller et al (2011), in a pilot study on individuals with NAFLD, did not find significant changes in blood glucose after a 3-mo intervention using Lactobacillus bulgaricus and Streptococcus thermophilus. In the study of Bhathena et al (2013), treatment with Lactobacillus fermentum for 12 wk had no significant effect on glucose levels in hamsters. On the other hand, in some animal and human studies, probiotics improved serum elevated glucose (Paik et al, 2005;Yadav et al, 2008;Ejtahed et al, 2011).…”